Convergence Investment Partners, LLC Halozyme Therapeutics, Inc. Transaction History
Convergence Investment Partners, LLC
- $431 Million
- Q4 2024
A detailed history of Convergence Investment Partners, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Convergence Investment Partners, LLC holds 34,713 shares of HALO stock, worth $1.95 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
34,713
Previous 27,562
25.95%
Holding current value
$1.95 Million
Previous $1.58 Million
5.27%
% of portfolio
0.38%
Previous 0.43%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
538Shares Held
123MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$992 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$726 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$373 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$229 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$192 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.84B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...